Xeris Pharmaceuticals Inc (XERS) Stock Analysis

Xeris Pharmaceuticals Inc (XERS) is a publicly traded company in the HEALTHCARE sector. It trades at $6.07, carries a market capitalization of $1.05B, a price-to-earnings ratio of 86.71. This page summarizes the public market data, fundamentals, and frequently asked questions for XERS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Xeris Pharmaceuticals Inc currently has a Neutral sentiment score of 0.04.

About Xeris Pharmaceuticals Inc

Xeris Pharmaceuticals, Inc. is a pioneering specialty pharmaceutical company headquartered in Chicago, Illinois, dedicated to the development and commercialization of ready-to-use injectable and infusible drug formulations. Utilizing its proprietary formulation technology, Xeris enhances patient care by improving the delivery and efficacy of therapeutics across critical therapeutic areas, including diabetes and oncology. The company is strategically positioned to address unmet medical needs, ...

GNG Research Analysis

GNG Research scores Xeris Pharmaceuticals Inc (XERS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for XERS.

Frequently Asked Questions

Does XERS pay dividends?

Xeris Pharmaceuticals Inc (XERS) does not currently pay a regular dividend.

What is XERS's P/E ratio?

Xeris Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 86.71.

What is XERS's market cap?

Xeris Pharmaceuticals Inc (XERS) has a market capitalization of $1.05B with a current stock price of $6.07.